Noronha Sean, Stokes Victoria, Karavitaki Niki, Grossman Ashley
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
Endocrine. 2016 Feb;51(2):205-10. doi: 10.1007/s12020-015-0727-2. Epub 2015 Sep 4.
Dopamine agonists are the treatment of choice for all patients with prolactinomas. They are generally safe, effective, and well-tolerated. However, a link between their use and the development of impulse control disorders has been well recognized in the field of neurology for some time, and evidence for a similar effect in endocrine patients is emerging. This has mainly been revealed through clinical case reports, plus a small number of comparative studies of varying robustness. We review the current available literature and discuss the implications for clinical practice, in particular emphasizing the need for clinicians to be alert to these uncommon but serious adverse effects.
多巴胺激动剂是所有催乳素瘤患者的首选治疗药物。它们通常安全、有效且耐受性良好。然而，一段时间以来，在神经学领域，其使用与冲动控制障碍的发生之间的联系已得到充分认识，并且在内分泌患者中出现类似效应的证据也正在显现。这主要通过临床病例报告以及一些稳健性各异的比较研究得以揭示。我们回顾了当前可用的文献，并讨论了其对临床实践的影响，特别强调临床医生需要警惕这些罕见但严重的不良反应。
